What does ESBL-producing Gram-negative rods mean for empiric therapy in severe infections?

• A. They may resist beta-lactams such as third-generation cephalosporins; require carbapenems or others with activity against ESBL producers
• B. They are susceptible to beta-lactams including third-generation cephalosporins
• C. They require macrolides as first-line therapy
• D. They are unaffected by ESBL

Answer: (B)

ESBL-producing Gram-negative rods carry enzymes that break down many beta-lactam antibiotics, including third-generation cephalosporins. In severe infections, you can’t rely on those drugs because the organism may be resistant. The empiric choice must include an antibiotic with reliable activity against ESBL producers, most commonly a carbapenem (such as meropenem or imipenem) or another agent proven active against ESBL producers.

The idea that these organisms are susceptible to beta-lactams like third-generation cephalosporins is incorrect, and macrolides aren’t appropriate first-line therapy for these Gram-negative rods. ESBL production doesn’t mean the organism is unaffected by ESBL enzymes; it means those enzymes render many beta-lactams ineffective, guiding the need for a carbapenem or equivalent until susceptibilities are known.